Evidence map›Paper›PMID 32575430›Full record

ArticleInternational journal of molecular sciences2020

Optimization of a WGA-Free Molecular Tagging-Based NGS Protocol for CTCs Mutational Profiling.

Giuseppa De Luca, Barbara Cardinali, Lucia Del Mastro, Sonia Lastraioli, Franca Carli, Manlio Ferrarini, George A Calin, Anna Garuti, Carlotta Mazzitelli, Simona Zupo and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Giuseppa De LucaMolecular Diagnostic Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.ORCID 0000-0003-4877-1309
Barbara CardinaliBreast Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Lucia Del MastroBreast Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Sonia LastraioliMolecular Diagnostic Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Franca CarliDepartment of Pathology, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Manlio FerrariniDIMES, Anatomy Section, Medical School, University of Genova, 16132 Genova, Italy.
George A CalinDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, TX 77030, USA.
Anna GarutiDepartment of Internal Medicine (Di.M.I.), University of Genova, 16132 Genova, Italy.
Carlotta MazzitelliBreast Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Simona ZupoMolecular Diagnostic Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Mariella DonoMolecular Diagnostic Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.ORCID 0000-0003-1280-0278
Ospedale Policlinico San Martino · ITUniversity of Genoa · ITThe University of Texas MD Anderson Cancer Center · US

Funding

Associazione Italiana per la Ricerca sul Cancro 20760Ministero della Salute 5x1000, funds 2015-2016
6 · The paper itself

Abstract

Molecular characterization of Circulating Tumor Cells (CTCs) is still challenging, despite attempts to minimize the drawbacks of Whole Genome Amplification (WGA). In this paper, we propose a Next-Generation Sequencing (NGS) optimized protocol based on molecular tagging technology, in order to detect CTCs mutations while skipping the WGA step. MDA-MB-231 and MCF-7 cell lines, as well as leukocytes, were sorted into pools (2-5 cells) using a DEPArray™ system and were employed to set up the overall NGS procedure. A substantial reduction of reagent volume for the preparation of libraries was performed, in order to fit the limited DNA templates directly derived from cell lysates. Known variants in

Indexed as

Biomarkers, TumorBreast NeoplasmsCell Line, TumorClass I Phosphatidylinositol 3-KinasesDNA Mutational AnalysisFeasibility StudiesFemaleHigh-Throughput Nucleotide SequencingHumansMCF-7 CellsNeoplastic Cells, CirculatingPrecision MedicineProto-Oncogene Proteins p21(ras)Single-Cell AnalysisTumor Suppressor Protein p53Biomarkers, TumorClass I Phosphatidylinositol 3-KinasesKRAS protein, humanPIK3CA protein, humanProto-Oncogene Proteins p21(ras)TP53 protein, humanTumor Suppressor Protein p53biomarkersbreast cancerCirculating Tumor Cellsliquid biopsymolecular taggingNext-Generation Sequencingprecision medicinesingle-cell genomicsWhole Genome Amplification-free

Identifiers

PMID32575430
PMCPMC7352435
OpenAlexW3036484575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.